Protalix BioTherapeutics/PLX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.

Ticker

PLX

Sector

Healthcare

Trading on

AMEX

Industry

Biotechnology & Drugs

Headquarters

Hackensack, United States

Employees

208

PLX Metrics

BasicAdvanced
$83M
Market cap
18.62
P/E ratio
$0.06
EPS
0.86
Beta
-
Dividend rate
$83M
0.86
$2.51
$1.03
9
1.375
0.968
68.556
11.555
6.23%
8.76%
44.48%
19.55%
18.622
1.389
2.771
2.781
18.963
45.00%
119.43%
1.36%

What the Analysts think about PLX

Analyst Ratings

Majority rating from 1 analysts.
Buy

PLX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-121.62% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$3.7M
-64.42%
Net income
-$4.5M
-25.00%
Profit margin
-121.62%
110.82%

PLX Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 133.33%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q2 24
Actual
$0.21
-$0.04
-$0.07
-
Expected
-$0.04
-$0.07
-$0.03
$0.02
Surprise
-625.00%
-42.86%
133.33%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Protalix BioTherapeutics stock?

Protalix BioTherapeutics (PLX) has a market cap of $83M as of June 24, 2024.

What is the P/E ratio for Protalix BioTherapeutics stock?

The price to earnings (P/E) ratio for Protalix BioTherapeutics (PLX) stock is 18.62 as of June 24, 2024.

Does Protalix BioTherapeutics stock pay dividends?

No, Protalix BioTherapeutics (PLX) stock does not pay dividends to its shareholders as of June 24, 2024.

When is the next Protalix BioTherapeutics dividend payment date?

Protalix BioTherapeutics (PLX) stock does not pay dividends to its shareholders.

What is the beta indicator for Protalix BioTherapeutics?

Protalix BioTherapeutics (PLX) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Protalix BioTherapeutics stock price target?

The target price for Protalix BioTherapeutics (PLX) stock is $12, which is NaN% below the current price of $. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Protalix BioTherapeutics stock

Buy or sell Protalix BioTherapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing